Episode Details

In this conversation, Dr. Gladden and Aubrey de Grey discuss the rapid advancements in the field of longevity research, emphasizing the importance of a systems biology approach to understanding aging. They explore the uneven distribution of funding and interest in various areas of research, the role of basic science, and the potential of stem cell therapies. The discussion highlights the need for a comprehensive strategy in addressing aging and the promising results from recent mouse trials. In this conversation, Aubrey de Grey discusses innovative approaches to senolytics and therapeutic combinations aimed at extending human lifespan. He emphasizes the importance of funding and research priorities in longevity, the role of AI in aging research, and the need to mobilize society against aging, drawing parallels to the COVID-19 pandemic. De Grey also elaborates on the hallmarks of aging and their implications for future research, while sharing his personal longevity strategies and practices.

For Audience

Join the other 20,000+ high-performers getting weekly insights on biological reversal, exponential strategies, and Life Energy optimization→ https://start.gladdenlongevity.com/subscribe If you're ready to measure your 60+ biological ages and build a personalized reversal plan, apply for a discovery call here → https://start.gladdenlongevity.com/apply-now Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/!

Takeaways

· The longevity field is advancing rapidly with increased funding.

· Interest in aging research is unevenly distributed.

· A systems biology approach is essential for understanding aging.

· Basic science is critical for developing effective interventions.

· Stem cell therapies show promise in treating age-related diseases.

· Rejuvenation should be viewed as an ongoing process.

· Combining multiple interventions may yield better results.

· Personalization of treatments is crucial for effectiveness.

· Understanding the body's responses can lead to better outcomes.

· Future trials will explore a wider range of interventions. We're using a vitaclax that is no longer toxic to platelets.

· The